The U.S. Food and Drug Administration on Friday approved Pulmonx Inc's valve to treat a severe form of obstructive lung disease, most often characterized by shortness of breath.
The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer.
Cardinal Health Inc's quarterly profit missed analysts' expectations as inventory and cost issues hurt its Cordis medical device unit, and the U.S. drug distributor said it saw prices of generic drugs fall more than expected.
Drug distributor AmerisourceBergen Corp posted a better-than-expected quarterly profit on Wednesday and said it expects its Memphis facility to be fully operational by fiscal 2019, sending its shares up 5 percent.
Laboratory Corp of America Holdings posted a quarterly profit on Wednesday that beat analysts' estimates, helped by higher demand at the unit performing clinical trials for drugmakers, and prompting the company to raise its full-year revenue target.
Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results.
AmerisourceBergen Corp on Tuesday said it received a grand jury subpoena from U.S. prosecutors seeking documents related to laboratory testing procedures at a facility that produces around half of the compounded drugs it supplies.
U.S. drug wholesaler McKesson Corp said prices of generic drugs were still competitive, but not as volatile as in 2017 when prices fell sharply, which should help the company as it benefits from a major tie-up with Walmart.
DaVita Inc , the biggest U.S. dialysis services provider, swung to a third-quarter loss due to an impairment charge it took for the continued underperformance of its Medical Group healthcare delivery and management unit.
AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry.